The depletion of SOS1 markedly inhibits cell growth either in vitro or in vivo and significantly increases the sensitivity of chronic myeloid leukemia cells to imatinib. This evidence concerns the gene SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive.